Rabbit Anti-Human BTK (a.a. 28-184) Polyclonal antibody

Over the past decade, covalent kinase inhibitors (CKI) have seen a resurgence in drug discovery. Covalency affords a unique set of advantages as well as challenges relative to their non-covalent counterpart. After reversible protein target recognition and binding, covalent inhibitors irreversibly modify a proximal nucleophilic residue on the protein via reaction with an electrophile. To date, the acrylamide group remains the predominantly employed electrophile in CKI development, with its incorporation in the majority of clinical candidates and FDA approved covalent therapies. Nonetheless, in recent years considerable efforts have ensued to characterize alternative electrophiles that exhibit irreversible or reversibly covalent binding mechanisms towards cysteine thiols and other amino acids. This review article provides a comprehensive overview of CKIs reported in the literature over a decade period, 2007-2018. Emphasis is placed on the rationale behind warhead choice, optimization approach, and inhibitor design. Current FDA approved CKIs are also highlighted, in addition to a detailed analysis of the common trends and themes observed within the listed data set.

Ibrutinib-based therapy represents a recent success in managing high-risk CLL patients with 17p/TP53deletion. However, a subset of CLL patients are resistant to therapy. Deletion of lipoprotein lipase (LPL) has been postulated as a potential evasion mechanism to ibrutinib-based therapy. In this study, we assessed forLPLdeletion by fluorescence in situ hybridization in 176 consecutive CLL patients with 17p/TP53deletion. LPL deletion was detected in 35 (20%) of CLL patients. Patients withLPLdeletion (del) showed a higher frequency of CD38 expression but have comparable frequencies of somatic hypermutation and ZAP-70 expression compared with patients with normal (nml)LPL. Gene mutation analysis showed thatTP53was mutated in 68% ofLPL-del versus 91% ofLPL-nml patients. The overall response to ibrutinib-based therapy was 57%, including 37% complete remission (CR) and 20% partial remission (PR) in patients withLPL-del versus 90% (56% CR and 34% PR) in patients withLPL-nml (p < 0.001).LPL-del patients also showed a poorer overall survival (OS) compared with patients withLPL-nml (median OS, 236 months versus undefined,p < 0.001). In summary, the data presented establish an association betweenLPLdeletion, resistance to ibrutinib-based therapy, and poorer overall survival inTP53-deleted CLL patients. We suggest thatLPLdeletion might be utilized as a biomarker for risk stratification and to predict therapeutic response in this high-risk group of CLL patients.